Drug Trial Radar · NCT05660642
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Feb 10, 2023
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Beckley Psytech LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).
Conditions
- Treatment Resistant Depression
Interventions
BPL-003Drug
Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. To assess the safety and tolerability of single or multiple intranasal doses of BPL-003 in patients with treatment resistant depressionTime frame: Baseline to 12 weeks post dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
MAC Clinical Research
Liverpool, United Kingdom · Recruiting
Hammersmith Medicines Research
London, United Kingdom · Recruiting
King's College London, Clinical Trials Facility
London, United Kingdom · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.